Relationship between HuR and tumor drug resistance

• Qiancheng Ma ^[1] ; Qiliang Lu ^[3] ; Xiangxiang Lei ^[4] ; Jie Zhao ^[1] ; Wen Sun ^[2] ; Dongsheng Huang ^[5] ; Qing Zhu ^[1] ; Qiuran Xu ^[5]
  1. [1] Zhejiang University of Technology

     Zhejiang University of Technology

     China

     
  2. [2] Zhejiang Chinese Medical University

     Zhejiang Chinese Medical University

     China

     
  3. [3] Qingdao Medical College, Qingdao University, Qingdao, 266000, China
  4. [4] Hangzhou Medical College, Hangzhou, 310053, China
  5. [5] The Key Laboratory of Tumor Molecular Diagnosis, and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, 310014, China

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 7 (July), 2023, págs. 1999-2014
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Human resistance protein R (HuR), also known as embryonic lethal abnormal visual-like protein (ELAVL1), is an RNA-binding protein widely expressed in vivo that affects the mRNA stability of targeted and is involved in post-transcriptional regulation. Recent studies have shown that HuR is aberrantly expressed in different human cancers and is an essential factor in poor clinical prognosis. The role of HuR in numerous tumors suggests that it could be a new target for tumor therapy and as a marker for efficacy and prognostic assessment. This review focuses on the relationship between HuR and drug resistance in different tumors and briefly describes the structure, function, and inhibitors of HuR. We summarize the mechanisms by which HuR causes tumor resistance and the molecular targets affected.